摘要
Abstract
Objective To evaluate the clinical values of serum HE4 and CA125 as biomarkers for diagnosis of ovarian cancer and benign ovarian tumors.Methods 38 patients with ovarian cancer (Case Group) and 42 patients with benign ovarian tumors (Control Group) were recruited in this study.The serum level of HE4 and CA125 were tested by ELISA assay.The diagnostic sensitivity,specificity,positive likely hood ratio,negative likely hood ratio and area under the ROC curve for ovarian cancer and benign ovarian tumors were diagnosed by ROC curve.Results The serum level of HE4 and CA125 in the Case Group were significant higher than that in the Control Group (P<0.05).The diagnostic sensitivity,specificity,positive likely hood ratio,negative likely hood ratio and area under the ROC curve were 74.4%,71.9%,5.41(95%CI:2.88-10.36),0.56(0.21-0.78) and 0.87(95%CI:0.80-0.95) for serum HE4,respectively.And 80.6%,75.4%,6.23(95%CI:3.12-13.64),0.48(0.19-0.718)and 0.94(95%CI:0.89-0.99) for serum CA125,respectively.Conclusion The serum HE4 and CA125 can be biomarkers for diagnosis of ovarian cancer and benign ovarian tumors.关键词
人附睾蛋白4/糖类抗原125/鉴别诊断/卵巢癌Key words
HE4/CA125/diagnosis/ovarian cancer分类
医药卫生
